The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

Revolution Medicines, a US-based precision oncology drug developer exploiting research from multiple universities, set terms yesterday for an initial public offering set to raise up to $160m.
The company set the range for the offering at $14 to $16 and plans to issue 10 million shares on the Nasdaq Global Market next week.
Founded in 2014, Revolution is working on therapies for a range of cancer indications. It is focusing on inhibitors of frontier targets, proteins that…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in